Literature DB >> 16320832

Unique expression and regulatory mechanisms of EG-VEGF/prokineticin-1 and its receptors in the corpus luteum.

Tatiana Kisliouk1, Helena Podlovni, Rina Meidan.   

Abstract

Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) or Prokineticin-1 (PK-1) is a novel cysteine-rich protein that belongs to the AVIT protein family. EG-VEGF/PK-1, described as selective angiogenic mitogen, is widely expressed in different tissues including steroidogenic endocrine glands. This review summarizes the expression and functions of EG-VEGF/PK-1 in corpus luteum (CL)-derived cells: endothelial and steroidogenic cell types. EG-VEGF/PK-1 mRNA is expressed by luteal steroidogenic cells of human, rat and bovine ovaries, but was absent from the luteal Endothelial cells CLEC. Luteal EC expressed high levels of both PK-receptors PK-R1 and PK-R2 - the two G protein-coupled PK-1 receptors. Interestingly, expression of EG-VEGF/PK-1 and VEGF were inversely regulated in human and bovine luteinized granulosa cells. EG-VEGF/PK-1 elevated [3H]-thymidine incorporation, MAPK activation and c-jun/fos mRNA expression and enhanced LEC proliferation. EG-VEGF/PK-1 also inhibited serum starvation-induced apoptosis in these cells. Stress conditions such as serum withdrawal, TNFalpha and chemical hypoxia markedly increase PK-R2 expression, whereas mRNA levels of PK-R1 remain unchanged, implying that the anti-apoptotic effect of PK-1 on LEC may be mediated via PK-R2. Besides its direct mitogenic and anti-apoptotic effects, EG-VEGF/PK-1 elevated VEGF mRNA expression in bovine luteal steroidogenic cells, which possesses only PK-R1. Together, these findings suggest an important role for PK-1 in luteal function by acting as a mitogen and survival factor in LEC. Nevertheless, the inverse regulation of EG-VEGF/PK1 and VEGF mRNA expression by ovarian cells and the distribution of its receptors may suggest that in addition to its angiogenic effects, EG-VEGF/PK-1 may also play other roles in ovary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16320832     DOI: 10.1016/j.aanat.2005.07.005

Source DB:  PubMed          Journal:  Ann Anat        ISSN: 0940-9602            Impact factor:   2.698


  7 in total

Review 1.  The prokineticins: a novel pair of regulatory peptides.

Authors:  Qun-Yong Zhou
Journal:  Mol Interv       Date:  2006-12

2.  Revisiting the role of hCG: new regulation of the angiogenic factor EG-VEGF and its receptors.

Authors:  S Brouillet; P Hoffmann; S Chauvet; A Salomon; S Chamboredon; F Sergent; M Benharouga; J J Feige; N Alfaidy
Journal:  Cell Mol Life Sci       Date:  2011-12-03       Impact factor: 9.261

3.  Modulators of pain: Bv8 and prokineticins.

Authors:  Lucia Negri; Roberta Lattanzi; Elisa Giannini; Pietro Melchiorri
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 4.  Potential roles of the prokineticins in reproduction.

Authors:  David Maldonado-Pérez; Jemma Evans; Fiona Denison; Robert P Millar; Henry N Jabbour
Journal:  Trends Endocrinol Metab       Date:  2007-01-05       Impact factor: 12.015

Review 5.  The multiple roles of EG-VEGF/PROK1 in normal and pathological placental angiogenesis.

Authors:  Nadia Alfaidy; Pascale Hoffmann; Houssine Boufettal; Naima Samouh; Touria Aboussaouira; Mohamed Benharouga; Jean-Jacques Feige; Sophie Brouillet
Journal:  Biomed Res Int       Date:  2014-05-15       Impact factor: 3.411

Review 6.  Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis.

Authors:  Ana Silvia Corlan; Anca Maria Cîmpean; Adriana-Andreea Jitariu; Eugen Melnic; Marius Raica
Journal:  Int J Endocrinol       Date:  2017-03-12       Impact factor: 3.257

7.  Maternal exposure to low levels of corticosterone during lactation protects adult rat progeny against TNBS-induced colitis: A study on GR-mediated anti-inflammatory effect and prokineticin system.

Authors:  Manuela Zinni; Anna Rita Zuena; Veronica Marconi; Carla Petrella; Ilaria Fusco; Chiara Giuli; Nadia Canu; Cinzia Severini; Maria Broccardo; Vassilia Theodorou; Roberta Lattanzi; Paola Casolini
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.